SCHEMBL69423

SCHEMBL69423

O=C1COc2ccc(Cl)cc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.55
NOTUM Q6P988 1/20 0.51
CYP19A1 P11511 1/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PKM P14618 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
S100A4 P26447 1/20 0.43
AR P10275 1/20 0.43
KDM4E B2RXH2 1/20 0.41
HTT P42858 2/20 0.41
VHL P40337 1/20 0.41
ELOC Q15369 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10962363 0.85 MAOB (0.50) MAOBNOTUMCYP19A1MAPTMEN1
SCHEMBL568794 0.84 MAPT (0.57) MAOBCYP19A1MAPTMEN1KMT2A
SCHEMBL69670 0.81 MAOB (0.50) MAOBNOTUMCYP19A1MAPTPKM
SCHEMBL30451384 0.81 MAOB (0.50) MAOBNOTUMCYP19A1MAPTPKM
SCHEMBL3553595 0.78 MAOB (0.57) MAOBNOTUMCYP19A1MAPTMEN1
SCHEMBL1181902 0.78 CTSL (0.46) MAOBNOTUMCYP19A1NPC1RAB9A
SCHEMBL22049536 0.78 MAOB (0.57) MAOBNOTUMCYP19A1MAPTMEN1
SCHEMBL5539912 0.78 HSD17B10 (0.45) MAOBNOTUMMAPTMEN1KMT2A
SCHEMBL3223921 0.76 MAPT (0.60) MAOBMAPTMEN1KMT2ANPC1
SCHEMBL3045957 0.76 HSD17B10 (0.44) MAOBMAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380751-B Indanamine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2025-03-07 CN disclosed
CN-116947832-B Ligustrazine derivative, preparation method and medical application thereof 江西中医药大学 2023-12-22 CN disclosed
CN-116947832-A Ligustrazine derivative, preparation method and medical application thereof 江西中医药大学 2023-10-27 CN disclosed
CN-114380751-A Indane amine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2022-04-22 CN disclosed
CN-114315736-A Indane amine derivatives, preparation method and application thereof 甫康(上海)健康科技有限责任公司 2022-04-12 CN disclosed
US-9783522-B2 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-10-10 US disclosed
US-9783522-B2 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-10-10 US disclosed
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-16 US disclosed
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-16 US disclosed
EP-3121176-A1 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY Families of Spinal Muscular Atrophy (US) 2017-01-25 EP disclosed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 US disclosed
US-6391902-B2 TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION SUCH AS INCONTINENCE AND IRRITABLE BOWEL SYNDROME AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
CN-1333774-A Substituted benzofuranodindoles and indenoindoles as novel potassium channel openers AMERICAN HOME PROD (US) 2002-01-30 CN disclosed
US-20010047026-A1 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers AMERICAN HOME PRODUCTS CORPORATION 2001-11-29 US disclosed
EP-1135393-A2 SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS AMERICAN HOME PRODUCTS CORPORATION (US) 2001-09-26 EP disclosed
US-6288099-B1 COMPOUNDS SUCH AS 8-BROMO-10H-BENZO(4,5)FURO(3,2-B)INDOLE-1-CARBOXYLIC ACID USED TO TREAT DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRATION SUCH AS URINARY INCONTINENCE AND IRRITABLE BOWL SYNDROME AMERICAN HOME PRODUCTS CORPORATION 2001-09-11 US disclosed
WO-2000034285-A2 SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
US-4895860-A ANTIDIABETIC, ANTILIPEMIC AMERICAN HOME PRODUCTS CORPORATION (US) 1990-01-23 US disclosed
US-RE32196-E PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS LILLY INDUSTRIES LIMITED (GB) 1986-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF ENPP2, ATXN2, ATXN2L MAOB 227/4885NOTUM 4508/4885CYP19A1 4273/4885
US-20010047026-A1 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers KCNJ2, KCNN3, KCNN2 MAOB 1452/4885NOTUM 4295/4885CYP19A1 2050/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 MAOB 176/4885NOTUM 3106/4885CYP19A1 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.